Acumen Pharmaceuticals, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Acumen is a clinical-stage biopharmaceutical company with one disclosed drug candidate, ACU193, an antibody targeting amyloid-beta oligomers for Alzheimer’s disease. The company reported no product revenue.
Financial performance and liquidity
- Operating expenses: $9.2 million, up $5.4 million (143%) from $3.8 million a year earlier. Research and development expense rose to $6.0 million from $2.6 million; general and administrative expense rose to $3.2 million from $1.2 million.
- Losses: Operating loss was $9.2 million versus $3.8 million. Net loss was $9.1 million versus $27.0 million, and comprehensive loss was $9.7 million versus $27.0 million. The prior-year net loss included $23.2 million of noncash expense from changes in the fair value of preferred-stock-related liabilities; therefore, the year-over-year net-loss improvement does not represent lower operating costs. Q1 2022 included a $0.6 million unrealized loss on marketable securities.
- Cash flow: Operating cash use was $8.3 million, compared with $2.4 million in Q1 2021. Investing cash use was $5.1 million, primarily reflecting purchases and maturities of marketable securities. Cash and cash equivalents decreased by $13.4 million during the quarter.
- Liquidity: At March 31, cash and cash equivalents were $108.8 million and marketable securities were $108.0 million, totaling $216.7 million. Working capital was $188.1 million. Management estimated these resources would fund operating expenses and capital requirements at least through 2025, subject to assumptions that may prove incorrect.
- Debt and obligations: No borrowings or debt balance are reported. Total liabilities were $4.0 million, including $0.2 million in operating lease liabilities. The filing identifies no material legal proceedings or material litigation contingencies.
- Margins: Not meaningful because the company reported no revenue. Basic and diluted loss per share was $0.23, compared with $64.41 in Q1 2021; the large per-share comparison also reflects the post-IPO share count, which was 40.5 million weighted-average shares versus 419,124.
Material changes and business update
- Operating expenses increased as the company advanced its clinical program and incurred higher consulting, CRO, personnel, insurance and legal costs, among other items.
- The Phase 1 INTERCEPT-AD trial is a randomized, double-blind, placebo-controlled U.S. study of approximately 62 patients with early Alzheimer’s disease. It evaluates safety, tolerability and proof of mechanism, including target engagement.
- Site activation and enrollment were ongoing. The company cited COVID-19-related delays and said it was expanding the anticipated number of trial sites. It expected to report topline data in the first half of 2023 based on then-current site activations and enrollment rates.
- Marketable securities had $0.8 million of cumulative unrealized losses at quarter-end, attributed primarily to interest-rate and market-credit-spread changes. The company said it did not intend, and was not more likely than not required, to sell the securities before recovery.
Outlook, risks and other items
- Acumen expects expenses and operating losses to increase as it advances ACU193, develops its organization and incurs public-company costs. It has no committed external funding source and may need additional capital; future equity financing could dilute shareholders, while debt or partnership financing could impose restrictions or require relinquishing rights.
- Key risks include clinical safety or efficacy results, trial enrollment and site delays, reliance on third-party trial and manufacturing providers, regulatory outcomes, competition, intellectual-property protection, and the potential effects of COVID-19, inflation, market volatility and geopolitical events.
- The company adopted lease-accounting guidance in January 2022, recording approximately $0.2 million in right-of-use assets and lease liabilities. It reported effective disclosure controls as of March 31, 2022 and no material change in internal control over financial reporting during the quarter.
- There was no new guidance beyond the stated cash runway estimate and trial-data timing. The company cautioned that forward-looking expectations depend on assumptions and may differ from actual outcomes.
Important facts for investors to verify
- Whether INTERCEPT-AD enrollment and site activation remain on track, and whether topline results are still expected in the first half of 2023.
- Whether cash use and operating expenses remain consistent with management’s estimate of funding through at least 2025.
- How future trial costs, clinical results, regulatory requirements and any financing or collaboration needs may affect the company’s cash runway and shareholder dilution.
- Whether unrealized losses in the securities portfolio remain interest-rate related and whether the company’s assessment of its ability to hold the investments remains valid.